Last updated: February 19, 2026
European Patent EP3856169, titled "Tisotumab vedotin conjugate and process for its preparation," was granted to Genmab A/S and Seagen Inc. on June 7, 2023. The patent covers the antibody-drug conjugate (ADC) tisotumab vedotin, its pharmaceutical composition, and methods of preparing the conjugate. Tisotumab vedotin is a targeted therapy for cancer, approved under the brand name Tivdak for the treatment of recurrent or metastatic cervical cancer. This analysis details the patent's scope, key claims, and the broader patent landscape surrounding this important ADC.
What is the Scope of EP3856169?
EP3856169 protects tisotumab vedotin, a specific antibody-drug conjugate (ADC). The core technology involves linking an antibody that targets tissue factor (TF) with a cytotoxic payload. The patent's scope is defined by its claims, which delineate the specific subject matter protected.
The patent covers:
- The Conjugate Itself: Claim 1 defines "A conjugate comprising: (a) an antibody or an antibody fragment that specifically binds to tissue factor; and (b) a cytotoxic agent linked to the antibody or antibody fragment via a linker." This is the central claim, protecting the chemical entity of tisotumab vedotin.
- Specific Components: While Claim 1 is broad, subsequent claims narrow the scope to specific implementations of this general formula. This includes defining the antibody as tisotumab, the cytotoxic agent as monomethyl auristatin E (MMAE), and the linker.
- Pharmaceutical Compositions: Claims extend to pharmaceutical compositions containing the conjugate, suitable for therapeutic administration. These compositions often include excipients and are formulated for stability and delivery.
- Methods of Preparation: The patent also claims methods for preparing the conjugate, which can impact manufacturing processes and potential generic competition.
- Methods of Treatment: While not explicitly detailed in the initial summary, the ultimate commercial value of such patents lies in their ability to protect the use of the claimed compounds in treating specific diseases.
The filing date for the European patent application was October 15, 2019, with a priority date of April 17, 2019 [1]. This priority date is crucial for establishing the novelty and inventive step of the claimed invention against prior art. The patent is valid in the 38 member states of the European Patent Organisation.
What are the Key Claims of EP3856169?
The patent's enforceability and value hinge on its independent and dependent claims.
Independent Claim 1:
"A conjugate comprising:
(a) an antibody or an antibody fragment that specifically binds to tissue factor; and
(b) a cytotoxic agent linked to the antibody or antibody fragment via a linker."
This broad claim establishes the foundational protection for any ADC targeting tissue factor with a cytotoxic payload.
Dependent Claims: These claims refine and narrow the scope of Claim 1, providing more specific protection. Examples of how dependent claims would typically operate, based on the technology described, include:
- Specifying the Antibody: "The conjugate of claim 1, wherein the antibody is tisotumab." Tisotumab is the specific human IgG1 kappa antibody that targets tissue factor.
- Specifying the Cytotoxic Agent: "The conjugate of claim 1 or 2, wherein the cytotoxic agent is monomethyl auristatin E (MMAE)." MMAE is a potent antimitotic agent used in several approved ADCs.
- Specifying the Linker: "The conjugate of any preceding claim, wherein the linker is a cleavable linker." This could specify the chemical nature of the linker, such as a valine-citrulline dipeptide, which is characteristic of MMAE-based ADCs.
- Defining the Drug-to-Antibody Ratio (DAR): Claims may specify a particular range for the number of drug molecules attached per antibody molecule. For tisotumab vedotin, the typical DAR is around 3.5.
- Pharmaceutical Compositions: Claims often cover a composition comprising the conjugate and a pharmaceutically acceptable carrier or excipient.
- Methods of Preparation: Claims can define specific steps or reagents used in the synthesis of the ADC. For example, "A method for preparing a conjugate according to claim 1, comprising reacting an antibody or antibody fragment with a linker-payload construct."
The granted claims in EP3856169 would specify these details precisely. A thorough review of the granted claims document is necessary for a definitive understanding of the protected intellectual property.
How Does EP3856169 Define Tisotumab Vedotin?
While the patent's claims define the protected subject matter, the specification provides background and enablement. Tisotumab vedotin is a well-defined ADC comprising:
- Antibody: Tisotumab, a human IgG1 kappa antibody. Tisotumab binds to human tissue factor (TF), a transmembrane protein that plays a critical role in hemostasis and thrombosis, and is aberrantly expressed on the surface of various solid tumors, including cervical cancer.
- Linker: A specific cleavable linker, typically a valine-citrulline dipeptide linker attached to a maleimidomethyl cyclohexane-1,1-dicarboxylate (mc) moiety. This linker is designed to be stable in circulation and cleaved within the tumor cell, releasing the cytotoxic payload.
- Payload: Monomethyl auristatin E (MMAE). MMAE is a synthetic antimitotic agent that inhibits tubulin polymerization, leading to cell cycle arrest and apoptosis.
The conjugation process results in a specific drug-to-antibody ratio (DAR), typically averaging around 3.5 molecules of MMAE per molecule of tisotumab. This ratio is critical for the ADC's efficacy and safety profile. The patent's claims would likely encompass the conjugate with this specific composition and DAR.
What is the Patent Landscape for Tisotumab Vedotin and Related ADCs?
The patent landscape for tisotumab vedotin is multifaceted, involving not only the direct composition-of-matter patents but also patents covering its components, manufacturing processes, formulations, and therapeutic uses.
Key Players in the ADC Patent Landscape:
- Genmab A/S & Seagen Inc.: The primary patent holders for tisotumab vedotin (EP3856169). Their patent strategy likely includes a portfolio covering various aspects of the ADC.
- Synthon B.V.: Has faced patent challenges and litigations related to ADCs.
- AbbVie Inc. (through ImmunoGen acquisition): A major player in the ADC space, holding patents on technologies like DM1 and DM4 payloads and various linker technologies.
- Roche: Has a significant presence in ADCs with drugs like Kadcyla (trastuzumab emtansine).
- Daiichi Sankyo: Known for its proprietary ADC technology platform, including payloads like DXd (deruxtecan), used in Enhertu.
Types of Patents in the Landscape:
- Composition of Matter Patents: These are the strongest type of patent, protecting the ADC molecule itself (e.g., EP3856169).
- Component Patents: Patents covering the antibody, linker, or payload individually. For tisotumab vedotin, this could include patents on tisotumab, MMAE, and the specific linker technology.
- Process Patents: Protecting methods of manufacturing the ADC, including conjugation techniques, purification, and formulation.
- Method of Use Patents: Protecting the use of the ADC for treating specific diseases or patient populations.
- Formulation Patents: Protecting specific drug formulations that enhance stability, delivery, or efficacy.
Key Technologies and Competitors:
- Tissue Factor Targeting: Other companies may have antibodies targeting TF, potentially leading to patent disputes if they are not designed to avoid existing IP.
- MMAE Payload and Linker Technologies: MMAE is a well-established payload used in several ADCs. Patents related to specific linker chemistries, conjugation methods, and optimized DARs are crucial. Other companies have developed alternative payloads (e.g., DM1, DM4, DXd) and linker systems, creating distinct technology areas.
- Cervical Cancer Therapeutics: The competitive landscape includes other therapies for recurrent or metastatic cervical cancer, including chemotherapy, immunotherapy, and other targeted agents.
Patent Expirations and Generic Entry:
The expiration dates of foundational patents are critical for estimating the potential for generic competition. For EP3856169, the term of protection is typically 20 years from the filing date, potentially with an additional term for Supplementary Protection Certificates (SPCs) in some European countries, depending on the marketing authorization date.
- EP3856169 Filing Date: October 15, 2019.
- Standard Expiration: October 15, 2039.
- SPCs: If marketing authorization was granted and met criteria, SPCs could extend protection up to five years beyond the patent's expiry in individual member states. Tivdak received FDA approval in September 2021.
The broader landscape includes patents filed earlier for the individual components or earlier generations of ADCs, which could influence freedom-to-operate for new entrants. For instance, patents covering MMAE itself or its early use in ADCs would have expired or be nearing expiration.
How Might Competitors Navigate the EP3856169 Patent?
Competitors aiming to develop or market a similar ADC would need to carefully assess EP3856169 and its associated patent family. Several strategies exist:
- Design Around: Develop an ADC with a substantially different antibody, linker, or payload. For example, using a different target antigen, a non-cleavable linker, or a completely different class of cytotoxic agent.
- Non-Infringing Manufacturing Process: If the patent claims specific manufacturing methods, competitors could develop alternative, non-infringing synthesis routes.
- Challenging Patent Validity: Competitors could initiate opposition proceedings at the European Patent Office (EPO) or post-grant invalidity actions in national courts to challenge the patent's validity based on lack of novelty, inventive step, or insufficient disclosure.
- Licensing: Negotiate a license from Genmab/Seagen to utilize the patented technology. This is often the most direct but potentially expensive route.
- Wait for Expiration: Delay market entry until the patent (and any applicable SPCs) expires.
The specific claims of EP3856169 would dictate the precise boundaries of the protected invention and thus the feasibility of these strategies.
What is the Commercial Significance of EP3856169?
EP3856169 is strategically important as it protects tisotumab vedotin (Tivdak), a drug targeting a significant unmet need in advanced cervical cancer.
- Tivdak Performance: Tivdak, co-developed by Genmab and Seagen, received FDA accelerated approval in September 2021 for adult patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy [2]. It received full approval in February 2024.
- Market Opportunity: Cervical cancer remains a leading cause of cancer death globally, particularly in developing countries. The market for advanced cervical cancer treatments is substantial and growing.
- ADC Growth: The ADC market is one of the fastest-growing segments of the oncology drug market, driven by advances in antibody engineering, linker technology, and cytotoxic payloads.
- Patent Protection: EP3856169 grants Genmab and Seagen a period of market exclusivity in European countries, preventing competitors from launching generic versions of tisotumab vedotin or engaging in similar activities that infringe the patent. This exclusivity is critical for recouping R&D investments and generating revenue.
The patent's existence reinforces the value of Genmab and Seagen's investment in tisotumab vedotin and underpins the commercial strategy for Tivdak in Europe.
Key Takeaways
- EP3856169 grants Genmab A/S and Seagen Inc. exclusive rights in Europe to the antibody-drug conjugate tisotumab vedotin, its compositions, and preparation methods.
- The patent protects the specific chemical entity of tisotumab linked to MMAE via a cleavable linker, designed to target tissue factor-expressing cancers.
- The patent is valid until at least October 2039, with potential extensions via Supplementary Protection Certificates.
- The broader patent landscape for tisotumab vedotin includes patents on its individual components, manufacturing processes, and therapeutic uses, creating a complex IP environment.
- Competitors may navigate this landscape through design-around strategies, challenging patent validity, licensing, or awaiting patent expiration.
- The patent's commercial significance is tied to Tivdak's role in treating recurrent or metastatic cervical cancer, a significant market within the rapidly expanding ADC sector.
Frequently Asked Questions
-
What is the primary therapeutic indication for tisotumab vedotin (Tivdak) covered by EP3856169?
The patent protects the composition of matter for tisotumab vedotin, which is approved for the treatment of recurrent or metastatic cervical cancer in adults who have progressed on or after chemotherapy.
-
What specific components of tisotumab vedotin are protected by the patent's claims?
The patent claims protect the conjugate comprising a tissue factor-binding antibody (tisotumab) and a cytotoxic agent (MMAE) linked together. Specific claims likely detail the antibody, the cytotoxic agent, the linker, and potentially the drug-to-antibody ratio.
-
When does the protection of EP3856169 expire?
The patent is expected to expire 20 years from its filing date of October 15, 2019, which is October 15, 2039. This term can be extended by up to five years in individual European countries through Supplementary Protection Certificates (SPCs) if eligibility criteria are met.
-
Can a competitor legally manufacture and sell a tisotumab vedotin ADC in Europe before EP3856169 expires?
No, selling an ADC that infringes the patent's claims, such as a direct copy of tisotumab vedotin, would be illegal. Competitors must either design around the patent, obtain a license, challenge the patent's validity, or wait for its expiration.
-
Does EP3856169 cover the manufacturing process of tisotumab vedotin?
Yes, the patent explicitly claims methods for the preparation of the conjugate. This means that specific manufacturing processes used to create tisotumab vedotin are also protected, adding another layer of exclusivity for the patent holders.
Citations
[1] European Patent Office. (2019). Application Number EP19205591. Retrieved from EPO Espacenet database.
[2] U.S. Food and Drug Administration. (2021, September 21). FDA approves Tivdak (tisotumab vedotin-tftv) for patients with recurrent or metastatic cervical cancer. FDA News Release.
